EDITORIAL
1July - September 2025 J Gandhara Med Dent Sci
How to cite this editorial
Faisal MS.Drug-Food Interactions:The Hidden Frontier in Clinical Practice.
J Gandhara Med Dent Sci.2025;12(3):1-2.https://doi.org/10.37762/jgmds.12-3.742
:
:
Muhammad Saleh Faisal
Chairman, Department of Pharmacology
Khyber Medical College, Peshawar
+92-347-5244271
drsalehfaisal@gmail.com
DRUG-FOOD INTERACTIONS: THE HIDDEN FRONTIER IN CLINICAL PRACTICE
,
As healthcare continues to shift toward precision medicine and patient-centred care, there is an urgent need to
revisit the pharmacological implications of food. Addressing this overlooked area requires a multipronged
approach, including the incorporation of DFIs into undergraduate and postgraduate medical education, as well as
the embedding of food interaction warnings and management strategies into clinical guidelines, particularly for
high-risk or commonly prescribed medications. This approach also involves incorporating DFI alert modules into
electronic health record systems and providing dietary guidance through patient counselling. In addition,
supporting research into unrecognised DFIs, including those involving nutraceuticals, herbal supplements, and
nutritional trends, is essential for identifying new risks. As medical educators, we need to bring drug-food
interactions from the footnotes to the forefront of clinical care. "It‘s time we regard food as a pharmacological
variable, not an afterthought. A meal can be medicine or a mistake when taken with certain drugs".
Clinically significant DFIs may result from changes in pharmaceutical, pharmacokinetic, or pharmacodynamic
properties. These interactions can influence the absorption, metabolism, distribution, or elimination of drugs in
various ways. For example, a high-fat meal can increase the solubility and, therefore, the absorption of lipophilic
drugs, potentially enhancing their effects. Conversely, certain components of food may inhibit or induce drug-
metabolising enzymes or transporters, such as cytochrome P450 enzymes or P-glycoprotein, which can lead to
increased toxicity or reduced therapeutic efficacy. Moreover , DFIs can alter pharmacodynamics by directly
affecting the mechanism of drug action at its site of effect. These interactions may result in additive, synergistic,
or antagonistic outcomes. Despite this complexity and potential clinical impact, DFIs are often given less
attention in clinical discussions and prescribing practices compared to drug-drug interactions. The most
important drug-food interactions are those associated with a high risk of treatment failure due to reduced
bioavailability in the fed state. These interactions are observed between milk and other dairy products, as well as
iron salts, tetracycline derivatives, and antacids containing polyvalent cations, resulting in a significant reduction
in their bioavailability of 50–90% or more.4,5 Numerous reports have documented interactions between drugs and
grapefruit juice (GFJ). GFJ contains furanocoumarins that inhibit intestinal CYP3A4, significantly increasing the
oral bioavailability of drugs such as felodipine, midazolam, and cyclosporine, which may potentially raise their
plasma concentrations to toxic levels. Furanocoumarins also increase the bioavailability of certain statins,
including simvastatin and atorvastatin, thereby increasing the risk of myopathy and rhabdomyolysis.6 Tyramine-
containing foods such as cheese, red wine, overripe bananas, yoghurt, etc., can trigger hypertensive crises in
patients taking monoamine oxidase inhibitors (MAOIs) by promoting excessive norepinephrine release.7
Warfarin, one of the most commonly prescribed oral anticoagulants, are affected by foods high in vitamin K.
Leafy greens like spinach, lettuce, parsley, and fenugreek can reduce the effectiveness of warfarin, potentially
resulting in sub-therapeutic INR levels and a higher risk of clot formation.8
A drug interaction is a situation in which a substance affects the activity of a drug, i.e., the effects are either
increased decreased, or a new effect is produced that neither substance causes on its own.1 It represents an
important source of medication errors.2 In contemporary clinical practice, drug-drug interactions (DDIs) are a
well-established concern, and there are protocols, alerts, and clinical guidelines in place to reduce harm.3 In
contrast, drug-food interactions (DFIs) have long been under-recognised and frequently overlooked in
pharmacotherapy. Several factors contribute to the neglect of DFIs. Firstly, DFIs receive little attention in most
clinical medicine curricula. While students are trained to screen for DDIs, few are taught about DFIs. Secondly,
most electronic medical record systems and pharmacy software offer limited or weak alerts for drug-food
interactions. This creates a blind spot in prescribing and dispensing practices. Thirdly, clinical workloads and
time constraints often prevent clinicians and pharmacists from providing dietary guidance. Moreover, significant
food effects complicate the development of new drugs, especially when clinical plans require controlled or
monitored food intake during dosing. So, predicting whether a drug or its product will exhibit a food effect in
humans remains a challenge.
2 J Gandhara Med Dent Sci July - September 2025
LICENSE: JGMDS publishes its articles under a Creative Commons Attribution Non-Commercial Share-Alike license (CC-BY-NC-SA 4.0).
COPYRIGHTS: Authors retain the rights without any restrictions to freely download, print, share and disseminate the article for any lawful purpose.
It includes scholarlynetworks such as Research Gate, Google Scholar, LinkedIn, Academia.edu, Twitter, and other academic or professional networking sites.
REFERENCES
1. Cascorbi I. Drug interactions-principles, examples and clinical consequences. Dtsch Arztebl Int. 2012;109(33–34):546–56.
https://doi.org/10.3238/arztebl.2012.0546. PMID: 22987027
2. Bates DW, Boyle DL, Vander Vliet MB, Schneider J, Leape L. Relationship between medication errors and adverse drug events. J Gen
Intern Med. 1995 Apr;10(4):199–205. https://doi.org/10.1007/BF02600255. PMID: 7610357
3. Li L, Baker J, Quirk R, Deidun D, Moran M, Salem AA, et al. Drug–Drug Interactions and Actual Harm to Hospitalised Patients: A
Multicentre Study Examining the Prevalence Pre and Post Electronic Medication System Implementation. Drug Saf. 2024
Jun;47(6):557–569. https://doi.org/10.1007/s40264-024-01412-w. PMID: 38478349
4. Schmidt LE, Dalhoff K. Food drug interactions. Drugs. 2002;62(10):1481–1502. https://doi.org/10.2165/00003495-200262100-00005.
PMID: 12093316
5. Tao RE, Prajapati S, Pixley JN, Grada A, Feldman SR. Oral Tetracycline Class Drugs in Dermatology: Impact of Food Intake on
Absorption and Efficacy. Antibiotics (Basel). 2023 Jul 5;12(7):1152. https://doi.org/10.3390/antibiotics12071152. PMID: 37419201
6. Dayyih WA, Al Ani I, Hailat M, Alarman SM, Zakaraya Z, Assab MA, et al. Review of grapefruit juice drugs interactions mediated by
intestinal CYP3A4 inhibition. J Appl Pharm Sci. 2024;14(5):059 068. https://doi.org/10.7324/JAPS.2024.160197. PMID: 37012345
7. Edinoff AN, Swinford CR, Odisho AS, Burroughs CR, Stark CW, Raslan WA, et al. Clinically relevant drug interactions with
monoamine oxidase inhibitors. Health Psychol Res. 2022;10(4):39576. https://doi.org/10.52965/001c.39576. PMID: 36425231
8. Bounda G A. Evaluation of pharmacist’s patient education on warfarin therapy and follow-up efficacy [thesis]. Nanjing: China
Pharmaceutical University; 2010.
Drug-Food Interactions: The Hidden Frontier in Clinical Practice